EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Eight versus twelve weeks of sofosbuvir-velpatasvir in treatment-naïve non-cirrhotic patients with chronic hepatitis C virus infection: Study protocol for a multicentric, open labelled, randomized, non-inferiority trial (RESOLVE trial)

Ashish Awasthi iD, Harshita Katiyar, Sumit Rungta, Amar Deep iD, Vinod Kumar, Shalimar, Ajay Kumar, Prachi Tiwari, Amit Goel iD

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0285725 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift PLOS ONE, 2023. Verfasst von Ashish Awasthi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Chronic Disease Control, New Delhi, India. Hauptthemen laut MEDLINE: Hepatitis C, Hepatitis C, Chronic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Indian Council of Medical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatitis C virus (HCV) is a common cause of liver cirrhosis and hepatocellular carcinoma. Globally, nearly 71 million people have chronic HCV infection, and approximately 399,000 dies annually. In patients without cirrhosis, HCV infection is treated with 12 weeks of sofosbuvir/velpatasvir combination. Results from available small, single-centre observational studies suggest that the sofosbuvir/velpatasvir combination given for 8 weeks may be as effective as the standard 12 weeks of treatment. We propose to compare the treatment response of 12 weeks versus 8 weeks of sofosbuvir/velpatasvir in non-cirrhotic people with chronic HCV infection.

Methods

This multicentric, randomized, open-label, non-inferiority trial will include 880 (2 arms x 440) treatment naïve, viraemic (HCV RNA >10,000 IU/mL), non-cirrhotic adults (age >18 years) with chronic hepatitis C. People who are at high-risk for HCV reinfection such as haemophiliacs, people who inject drugs, those on maintenance hemodialysis or having HIV will be excluded. The presence or absence of cirrhosis will be determined with a combination of history, examination, ultrasound, liver stiffness measured with transient elastography, APRI, FIB-4, and esophagogastroduodenoscopy. Participants will be randomized to receive either 8- or 12-week sofosbuvir/velpatasvir treatment. A blood specimen will be collected before starting the treatment (to determine the HCV genotype), after 4 weeks of treatment (for early virological response), and at 12 weeks after treatment discontinuation for SVR12.

Discussion

The study will provide data on the efficacy of 8 weeks of treatment as compared to the standard of care (12 weeks) in non-cirrhotic patients with chronic HCV infection. Treatment for a shorter duration may improve treatment compliance, reduce the cost of treatment, and ease the treatment implementation from a public health perspective.

Trial registration

Registered with Clinical Trial Registry of India ( http://ctri.nic.in ) Registration No. CTRI/2022/03/041368 [Registered on: 24/03/2022]—Trial Registered Prospectively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis CHepatitis C, ChronicAdolescentAdultHumansAntiviral AgentsGenotypeHepacivirusHeterocyclic Compounds, 4 or More RingsLiver CirrhosisMulticenter Studies as TopicRandomized Controlled Trials as TopicSofosbuvirTreatment OutcomeEquivalence Trials as TopicBenzimidazolesBenzopyransCarbamates

Substanzen

Antiviral AgentsHeterocyclic Compounds, 4 or More RingsSofosbuvirvelpatasvirBenzimidazolesBenzopyransCarbamates

Autor:innen und Institutionen

  • Centre for Chronic Disease Control, New Delhi, India.
  • Centre for Chronic Conditions and, Injuries, Public Health Foundation of India, Gurgaon, India.
  • Department of Hepatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
  • Department of Gastroenterology, King George Medical University, Lucknow, India.
  • Department of Gastroenterology, Institute of Medical Sciences, Banaras Hindu University, Lucknow, India.
  • Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi, India.

ORCID-Profile: Ashish Awasthi, Amar Deep, Amit Goel

Förderung

  • Indian Council of Medical Research

Zitieren

APA

Awasthi, A., Katiyar, H., Rungta, S., Deep, A., Kumar, V., Shalimar, Kumar, A., Tiwari, P., & Goel, A. (2023). Eight versus twelve weeks of sofosbuvir-velpatasvir in treatment-naïve non-cirrhotic patients with chronic hepatitis C virus infection: Study protocol for a multicentric, open labelled, randomized, non-inferiority trial (RESOLVE trial). PLOS ONE. https://doi.org/10.1371/journal.pone.0285725

Vancouver

Awasthi A, Katiyar H, Rungta S, Deep A, Kumar V, Shalimar, et al. Eight versus twelve weeks of sofosbuvir-velpatasvir in treatment-naïve non-cirrhotic patients with chronic hepatitis C virus infection: Study protocol for a multicentric, open labelled, randomized, non-inferiority trial (RESOLVE trial). PLOS ONE. 2023. doi:10.1371/journal.pone.0285725

BibTeX
@article{Awasthi2023,
  author = {Awasthi, Ashish and Katiyar, Harshita and Rungta, Sumit and Deep, Amar and Kumar, Vinod and Shalimar and Kumar, Ajay and Tiwari, Prachi and Goel, Amit},
  title = {Eight versus twelve weeks of sofosbuvir-velpatasvir in treatment-naïve non-cirrhotic patients with chronic hepatitis C virus infection: Study protocol for a multicentric, open labelled, randomized, non-inferiority trial (RESOLVE trial)},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0285725}
}
Kostenlos starten →